Squarepoint Ops LLC Acquires 16,484 Shares of CareDx, Inc (NASDAQ:CDNA)

Squarepoint Ops LLC grew its stake in CareDx, Inc (NASDAQ:CDNA - Free Report) by 7.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 231,235 shares of the company's stock after buying an additional 16,484 shares during the quarter. Squarepoint Ops LLC owned 0.43% of CareDx worth $4,951,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Swiss National Bank boosted its holdings in CareDx by 1.9% in the fourth quarter. Swiss National Bank now owns 98,600 shares of the company's stock valued at $2,111,000 after purchasing an additional 1,800 shares in the last quarter. Barclays PLC grew its holdings in CareDx by 123.8% during the third quarter. Barclays PLC now owns 98,505 shares of the company's stock worth $3,075,000 after acquiring an additional 54,482 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in CareDx by 59.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 327,343 shares of the company's stock worth $7,008,000 after acquiring an additional 122,356 shares during the period. KLP Kapitalforvaltning AS acquired a new position in CareDx during the fourth quarter worth $208,000. Finally, Principal Financial Group Inc. grew its holdings in CareDx by 6.5% in the fourth quarter. Principal Financial Group Inc. now owns 18,984 shares of the company's stock valued at $406,000 after purchasing an additional 1,151 shares during the last quarter.

Insider Activity

In other news, Director Christine Cournoyer sold 29,136 shares of CareDx stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $15.96, for a total value of $465,010.56. Following the completion of the transaction, the director now owns 37,045 shares in the company, valued at approximately $591,238.20. The trade was a 44.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Peter Maag sold 13,281 shares of the firm's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $17.23, for a total value of $228,831.63. Following the completion of the transaction, the director now owns 316,743 shares in the company, valued at $5,457,481.89. This represents a 4.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 59,382 shares of company stock valued at $934,509. 4.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts recently commented on CDNA shares. The Goldman Sachs Group decreased their price objective on CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. Wall Street Zen downgraded CareDx from a "buy" rating to a "hold" rating in a report on Monday, May 5th. HC Wainwright reiterated a "neutral" rating and set a $25.00 target price on shares of CareDx in a report on Monday, May 5th. Finally, Stephens reiterated an "overweight" rating and set a $40.00 target price on shares of CareDx in a report on Monday, May 5th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, CareDx presently has an average rating of "Moderate Buy" and a consensus target price of $30.33.

CareDx Trading Up 2.7%

Shares of CareDx stock traded up $0.45 on Friday, reaching $17.01. 127,695 shares of the company were exchanged, compared to its average volume of 893,856. The stock has a fifty day moving average price of $17.32 and a 200-day moving average price of $20.58. The firm has a market capitalization of $946.86 million, a price-to-earnings ratio of -6.29 and a beta of 2.27. CareDx, Inc has a fifty-two week low of $12.90 and a fifty-two week high of $34.84.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.03. The firm had revenue of $84.69 million for the quarter, compared to the consensus estimate of $84.56 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The business's quarterly revenue was up 17.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.03) earnings per share. On average, equities analysts anticipate that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.